This Article Full Text Full Text (PDF) All Versions of this Article: 100/5/712    most recent 01.RES.0000259579.35787.4ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Isenberg, J. S. Articles by Roberts, D. D. Search for Related Content PubMed PubMed Citation Articles by Isenberg, J. S. Articles by Roberts, D. D. Related Collections Peripheral vascular disease Remodeling Other Vascular biology Angiogenesis Ischemic biology - basic studies Related Article

(Circulation Research. 2007;100:712.)
© 2007 American Heart Association, Inc.

Integrative Physiology

Increasing Survival of Ischemic Tissue by Targeting CD47

Jeff S. Isenberg, Martin J. Romeo, Mones Abu-Asab, Maria Tsokos, Anna Oldenborg, Loretta Pappan, David A. Wink, William A. Frazier, David D. Roberts

From the Laboratory of Pathology (J.S.I., M.J.R., M.A.-A., M.T., D.D.R.) and Radiation Biology Branch (D.A.W.), Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Md; and Department of Biochemistry and Molecular Biophysics (A.O., L.P., W.A.F.), Washington University School of Medicine, St Louis, Mo.

Correspondence to J. S. Isenberg, MD, MPH, Laboratory of Pathology, Bldg 10, 2A33, National Cancer Institute, Bethesda, MD 20892-1500. E-mail isenberj{at}mail.nih.gov

Thrombospondin-1 (TSP1) limits the angiogenic and vasodilator activities of NO. This activity of TSP1 can be beneficial in some disease states, but endogenous TSP1 limits recovery of tissue perfusion following fixed ischemic injury in dorsal skin flaps in mice. Using mice lacking the TSP1 receptors CD36 or CD47, we now show that CD47 is the necessary receptor for limiting NO-mediated vascular smooth muscle relaxation and tissue survival following ischemic injury in skin flaps and hindlimbs. We further show that blocking CD47 or TSP1 using monoclonal antibodies and decreasing CD47 expression using an antisense morpholino oligonucleotide are effective therapeutic approaches to dramatically increase survival of soft tissue subjected to fixed ischemia. These treatments facilitate rapid vascular remodeling to restore tissue perfusion and increase skin and muscle viability. Thus, limiting CD47-dependent antagonism of NO-mediated vasodilation and vascular remodeling is a promising therapeutic modality to preserve tissues subject to ischemic stress.

Key Words: nitric oxide • thrombospondin-1 • ischemic tissue survival • CD47 • therapeutics

Related Article:

Targeting CD47: NO Limit on Therapeutic Potential

David J. Kaczorowski and Timothy R. Billiar
Circ. Res. 2007 100: 602-603. [Full Text] [PDF]

This article has been cited by other articles:

				J.-S. Silvestre, Z. Mallat, A. Tedgui, and B. I. Levy Post-ischaemic neovascularization and inflammation Cardiovasc Res, May 1, 2008; 78(2): 242 - 249. [Abstract] [Full Text] [PDF]

				J. S. Isenberg, D. D. Roberts, and W. A. Frazier CD47: A New Target in Cardiovascular Therapy Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 615 - 621. [Abstract] [Full Text] [PDF]

				J. S. Isenberg, F. Hyodo, L. K. Pappan, M. Abu-Asab, M. Tsokos, M. C. Krishna, W. A. Frazier, and D. D. Roberts Blocking Thrombospondin-1/CD47 Signaling Alleviates Deleterious Effects of Aging on Tissue Responses to Ischemia Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2582 - 2588. [Abstract] [Full Text] [PDF]

				R. Moura, M. Tjwa, P. Vandervoort, K. Cludts, and M. F. Hoylaerts Thrombospondin-1 Activates Medial Smooth Muscle Cells and Triggers Neointima Formation Upon Mouse Carotid Artery Ligation Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2163 - 2169. [Abstract] [Full Text] [PDF]

				O. I. Stenina, E. J. Topol, and E. F. Plow Thrombospondins, Their Polymorphisms, and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1886 - 1894. [Abstract] [Full Text] [PDF]

				D. J. Kaczorowski and T. R. Billiar Targeting CD47: NO Limit on Therapeutic Potential Circ. Res., March 16, 2007; 100(5): 602 - 603. [Full Text] [PDF]